This article aims to explore the role that clients play in research and how their experiences can contribute to psychotherapy process research. Following a broad outline of the findings of earlier process research, arguments why clients have not been at the forefront of researchers' methodologies are offered against those who recognize the value and importance of asking clients directly about their experiences. Examples of a range of studies are discussed where clients' views and experiences of different therapies, or where the individual components within a therapy, are the primary sources of data. Although this is the key focus, studies that consider the views of clients relating to more general areas of mental health are also referred to briefly.

No abstract

This study explores clients' experiences of Dialectical Behavioural Therapy (DBT). Five participants, all with a diagnosis of borderline personality disorder, were interviewed following a semi-structured format about their experiences of an NHS regional DBT programme. The interviews were transcribed and analysed using Interpretative Phenomenological Analysis (IPA). Three superordinate themes were identified consisting of a number of sub themes: joining a DBT Programme (external and internal factors); experience of DBT (specific and non specific factors); and evaluation of DBT (change, evaluation and role of the past and future). The study provides an insight into clients' experiences of DBT. The results are discussed in relation to clinical practice and future research.

Focal points □ The presentation focuses on the contribution that oncology pharmacists make to the work of the cancer networks □ The current contribution varies between networks but includes development of evidence‐based treatment guidelines, the setting up of network oncology pharmacist groups, audit, drug procurement, and research and development □ The recent establishment of the NHS Cancer Research Network will build upon the current contribution made to research and development by oncology pharmacists by their support of clinical trials and other activities □ The presentation reflects on the barriers and facilitators that exist for these roles and invites discussion on the potential for the future role of the pharmacist within the network structure